New Alzheimer's drug trial aims to tame brain inflammation
NCT ID NCT06745583
First seen May 14, 2026 · Last updated May 16, 2026 · Updated 1 time
Summary
This early study tests a new drug called EI-1071 in 15 people with mild to severe Alzheimer's disease. The main goal is to see if the drug is safe and tolerable over 4 weeks, and to measure its effect on brain inflammation using special PET scans. Participants must have stable Alzheimer's symptoms and be on steady medications for at least 8 weeks before joining.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MILD, MODERATE, OR SEVERE ALZHEIMER'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Taipei Veterans General Hospital
RECRUITINGTaipei, 112, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tri-Service General Hospital
RECRUITINGTaipei, 11490, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.